Hematologic Malignancy
B-Cell Neoplasm
CI-CAN-00000470Explore in graph →
HematologicNon-malignant2,097 active trials46 approved drugs301 evidence items
- NCIt
- C27907
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000470Explore in graph →
Clinical trials
7,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00423644 | A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b | completed | Phase 2 | 17 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01414855 | A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) | completed | Phase 2 | 100 | Genentech, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01559935 | Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma(CarBiRD) | completed | Phase 2 | 74 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02465060 | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | active not recruiting | Phase 2 | 6,452 | National Cancer Institute (NCI)NIH | 3 | Sep 29, 2026 | clinicaltrials |
| NCT03739814 | Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT05228470 | A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. | completed | Phase 2 | 39 | PfizerINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05354557 | Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) | active not recruiting | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05952024 | Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL(ACRUE) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT06179888 | Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | suspended | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06649812 | Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06876142 | Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07605416 | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial | recruiting | Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor | not yet recruiting | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07847957 | Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL | not yet recruiting | Phase 1 / Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03223610 | Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03412877 | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer | recruiting | Phase 2 | 285 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04973605 | A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 246 | BeOne MedicinesINDUSTRY | 13 | Sep 28, 2026 | clinicaltrials |
| NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies(CaDAnCe-101) | recruiting | Phase 1 / Phase 2 | 645 | BeOne MedicinesINDUSTRY | 16 | Sep 28, 2026 | clinicaltrials |
| NCT05288062 | Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05421663 | A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 166 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 28, 2026 | clinicaltrials |
| NCT05600686 | Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma | active not recruiting | Phase 2 | 24 | University of California, DavisOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05874193 | A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma(COSTA) | withdrawn | Phase 2 | 0 | Cristiana Costa Chase, DOOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06252675 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | University of California, San FranciscoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06350318 | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | recruiting | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06421675 | Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma(EMBRACE) | recruiting | Phase 2 | 40 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06524375 | A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period(BRAVE) | active not recruiting | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | recruiting | Phase 1 / Phase 2 | 258 | BeOne MedicinesINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07439653 | A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 155 | TORL Biotherapeutics, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07685717 | Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 50 | Jennifer WoyachOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07839247 | Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL | recruiting | Phase 2 | 33 | Xiaohui RenOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT01745588 | Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02458014 | Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02538198 | Lenalidomide Maintenance in Plasma Cell Myeloma | active not recruiting | Phase 2 | 108 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02619682 | Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT02649387 | Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy(MERIT) | completed | Phase 2 | 35 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03349450 | DPX-Survivac and Checkpoint Inhibitor in DLBCL(SPiReL) | completed | Phase 2 | 25 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03779854 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04133636 | A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma(CARTITUDE-2) | active not recruiting | Phase 2 | 208 | Janssen Research & Development, LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT04679012 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | active not recruiting | Phase 2 | 20 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04876248 | Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | active not recruiting | Phase 2 | 4 | Roswell Park Cancer InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05139017 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | recruiting | Phase 2 / Phase 3 | 290 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 25, 2026 | clinicaltrials |
| NCT05572229 | Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma(IFM2021-01) | active not recruiting | Phase 2 | 74 | University Hospital, LilleOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05783596 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | active not recruiting | Phase 2 | 47 | Reid Merryman, MDOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05907759 | Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
Data updated 13 hours agoSource updated Sep 29, 2026source: clinicaltrials